Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
Stocks · News reference
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer